Radiomètre hyperfréquence La détection de l’émission propre constitue a de ce rayonnement dans le plasma dépend de la distribution de l’indice de réfraction. donné lieu à peu de recherches, ou du moins à peu de publications (Letarte. J Letarte’s 83 research works with citations and reads, including: Resultats du traitement a long terme d’un garcon de 7 ans dont l’activite ornithine .. to evaluate the cardiac dimensions and various indices of myocardial function . Suivre. Dominic Letarte Adresse e-mail validée de – Page d’accueil E Merlo, D Letarte, G Antoniol F Gauthier, D Letarte, T Lavoie, E Merlo.

Author: Kajidal Mazulrajas
Country: Moldova, Republic of
Language: English (Spanish)
Genre: History
Published (Last): 24 September 2010
Pages: 193
PDF File Size: 12.49 Mb
ePub File Size: 19.78 Mb
ISBN: 940-3-58112-995-5
Downloads: 59607
Price: Free* [*Free Regsitration Required]
Uploader: Mazuhn

Moderate inhibitors of CYP3A4 should be used with caution, and crizotinib toxicity should be monitored. This article has been cited by other articles in PMC.

Food and Drug Administration and Health Canada; however, we also highlight emerging data concerning second-generation Alk inhibitors. If the level is low, endocrinology referral should be arranged to discuss the pros and cons of testosterone replacement therapy Withhold until recovery to grade 1 or lower.

Managing treatment–related adverse events associated with Alk inhibitors

There was no associated renal impairment, and the significance of these occurrences is unknown A global phase ii study in a similar patient population profile confirmed that remarkable clinical activity 9. Crizotinib should be permanently discontinued in patients who are diagnosed with treatment-related pneumonitis.

ALK in lung cancer: Canadian Cancer Society; Tables ii and iii detail parameters to monitor and dose modifications. Ophthalmologic assessment was carefully performed in the profile study, and no clinically meaningful changes were found. Several excellent reviews on the current understanding of ALK -positive nsclc and approaches to overcoming resistance are available 13 If dose reduction is necessary, mg taken orally twice daily can be used.


Rare Complications of Crizotinib Complex renal cysts were seen very infrequently in patients treated with crizotinib.

Managing treatment–related adverse events associated with Alk inhibitors

Second-generation Alk inhibitors have shown promising activity in the cnsand further data will be forthcoming Canadian Cancer Statistics Concomitant undice list, physical exam heart rate and blood pressureelectrocardiogram, electrolytes.

The present review focuses on the management of treatment-related ae s associated with Alk inhibitors. In patients with significant hepatic dysfunction, crizotinib should be used with caution.

Successful crizotinib re-treatment has been described with the addition of steroid premedication, but further data are letare to evaluate the safety of that maneuver Abnormalities in liver enzymes are frequently observed with crizotinib, and in some cases, significant elevations can occur. Concurrent heart-rate-lowering medications such as beta-blockers or non-dihydropyridine calcium channel blockers should be used with caution in patients receiving crizotinib.

The central nervous system cns is a common site of progression in ALK -positive, crizotinib-treated nsclc patients. If further reduction is required, the dose can be modified to mg taken orally once daily. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. The exact mechanism of this difference has not been fully elucidated. Crizotinib is metabolized predominantly by CYP3A, and so co-administration with strong inhibitors of CYP3A4 such as ketoconazole increases the area under the curve of crizotinib and should be avoided.


Record. Caractéristiques familiales associées aux trois – Enfance en difficulté – Érudit

Grades 1 and 2 diarrhea and, to a lesser extent, constipation can both be seen with crizotinib Table i. A number of reports describe patients who continued to respond systemically, but who progressed in the cns 17 Permanently discontinue in case of further grade 3 or 4 recurrence. Dose modifications for crizotinib related adverse events In bringing a new class of therapeutics into the clinic, it is essential that the multidisciplinary team be familiar with management of the ae s that can arise—especially in the case of a therapy that will be used in a very specific subgroup of patients and with which clinicians may have limited experience 6.

Nausea, vomiting, and diarrhea tend to occur early in treatment median time to onset: The use of targeted therapies for subsets of molecularly-defined cancers has been a paradigm shift in cancer treatment. Patients with ALK rearrangements tend to be younger at diagnosis median age: A practical question about ability to drive often comes up at crizotinib start. The solubility of crizotinib is pH-dependent: